A new study has been launched to analyze hypofractionated stereotactic body radiation therapy (SBRT) using Calypso Medical Technologies' GPS for the Body technology for real-time tracking of cancerous tumors during prostate radiation therapy.
The multicenter trial will test whether a short-course treatment regimen with continuous real-time evaluation of prostate motion with the Calypso system is safe and effective compared to conventional radiation therapy. The 39-month phase II study will enroll 66 patients who will receive five 30-minute treatment sessions in 7.4-Gy fractions over 15 to 19 calendar days -- much shorter than the conventional protocol of 40 to 45 daily treatments, which can take eight to nine weeks to complete.
Institutions participating in the study include the University of Michigan, Washington University, Fox Chase Cancer Center, Cedars-Sinai Medical Center, and Radiation Oncology Centers of Sacramento.
